Search results (17)
« Back to NewsGlowing dye helps surgeons eradicate prostate cancer
10 June 2024
A glowing marker dye that sticks to prostate cancer cells could help surgeons to remove them in real-time, according to a study led by the University of Oxford.
New funding for development of world's first lung cancer vaccine
22 March 2024
Oxford and UCL researchers seeking to create the world’s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.
Professor Eileen Parkes appointed to lead Oxford’s Experimental Cancer Medicine Centre
17 October 2023
Eileen Parkes, Associate Professor in Innate Tumour Immunology in the Department of Oncology, will lead the expansion of the centre’s programmes in early drug development and biomarker research.
Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies
27 July 2023
Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.
Multi-cancer blood test shows real promise in NHS trial
2 June 2023
An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.
Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene
29 September 2022
A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.
World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition
24 November 2021
Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.
Advancing radiotherapy technology through clinical trials
19 November 2021
Rob Stepney participated in a radiotherapy clinical trial in Oxford in 2021. He talks about his experience on the trial and accessing a state-of-the-art machine that uses real-time imaging to improve tumour targeting.
Oxford cancer clinical trials unit receives acclaimed nursing award
13 October 2021
The nursing team at the Early Phase Clinical Trials Unit has been awarded the Excellence in Cancer Research Nursing Award 2021.
Anti-cancer drug derived from fungus shows promise in clinical trials
7 October 2021
A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana has found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.
Oxford to assess revolutionary multi-cancer blood test in trial, for future implementation in the NHS
15 September 2021
A partnership between the University of Oxford and GRAIL, LLC will evaluate the use of a new, non-invasive, multi-cancer early detection test known as Galleri in suspected cancer patients.
University of Oxford Announces Opening of PanDox Phase 1 Study investigating Targeted Drug Delivery by Focused Ultrasound for Pancreatic Cancer
1 July 2021
The University of Oxford is pleased to announce commencement of enrollment for the Phase I PanDox study of thermosensitive liposomal doxorubicin triggered by focused ultrasound in patients with pancreatic cancer.
Professor Sibson secures further MRC DPFS funding
20 October 2020
Prof. Sibson together with her co-applicants Prof. Anthony, Dr Campbell and Prof. Middleton have now been awarded a second MRC DPFS grant, for £3.3 million, to acquire further preclinical data to support the case for clinical translation, to develop the mutTNF production for human use and to undertake pre-clinical toxicology.
Clinical researchers at Oxford University announce new collaboration with Janssen to detect blood cancers sooner
8 August 2019
The new 7-year research collaboration with Janssen Research & Development, LLC (Janssen) will study patients at higher risk of developing certain types of blood cancers that arise from the immune system, such as chronic lymphocytic leukaemia and multiple myeloma, to identify markers that could be used to predict who will go on to develop symptomatic disease.
10-Year Partnership with Genesis Care
7 February 2019
GenesisCare and the University of Oxford establish innovative 10-year research partnership to improve diagnosis and care for people with cancer.
Oxford collaborative science opens the way for a new drug for bowel cancer patients across the UK
30 June 2017
Today a new drug will become available for patients with bowel cancer as part of a national clinical trial; based on a scientific discovery made only two years ago at the University of Oxford.